Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
AngioDynamics Inc reported Q4 2024 EPS loss of $0.05 vs. consensus loss of $0.16. Q4 sales totaled $70.98 million, beating analyst consensus of $70.89 million. Guidance for FY 2025 expects net sales of $282 million-$288 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year. AngioDynamics announced a stock repurchase program of up to $15.0 million.
- AngioDynamics Inc reported Q4 2024 EPS loss of $0.05 vs. consensus loss of $0.16.
- Q4 sales totaled $70.98 million, beating analyst consensus of $70.89 million.
- Guidance for FY 2025 expects net sales of $282 million-$288 million.
- Med Tech segment net sales were $29.3 million, up 11.3% year over year.
- AngioDynamics announced a stock repurchase program of up to $15.0 million.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.